Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans.
about
CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cellsBiodegradable polymeric microsphere-based vaccines and their applications in infectious diseasesIntranasal immunization with Gal-inhibitable lectin plus an adjuvant of CpG oligodeoxynucleotides protects against Entamoeba histolytica challenge.Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine.A foreign protein incorporated on the Tip of T3 pili in Lactococcus lactis elicits systemic and mucosal immunity.Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans.Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2.Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginallyVaccines against gonorrhea: current status and future challenges.Mucosal immunity and vaccines.Influence of exogenous reproductive hormones on specific antibody production in genital secretions after vaginal vaccination with recombinant cholera toxin B subunit in humans.Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin aRandomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulationVaccination against Chlamydia genital infection utilizing the murine C. muridarum model.Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage formsChlamydia trachomatis vaccine research through the years.Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV.Mice intranasally immunized with a recombinant 16-kilodalton antigen from roundworm Ascaris parasites are protected against larval migration of Ascaris suum.Enteric pathogens as vaccine vectors for foreign antigen deliveryImmunologic uniqueness of the genital tract: challenge for vaccine development.Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties.Combined Oral and Intravenous Immunization Stimulates Strong IgA Responses in Both Systemic and Mucosal Compartments.Intranasal Vaccination Affords Localization and Persistence of Antigen-Specific CD8⁺ T Lymphocytes in the Female Reproductive Tract.Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.Stimulating an immune response? Oral sex is associated with less endometritis.Antiviral immune responses in the genital tract: clues for vaccines.Identification and characterization of gonococcal iron transport systems as potential vaccine antigens.New approaches to prophylactic human papillomavirus vaccines for cervical cancer preventionHIV/AIDS vaccines: a need for new concepts?Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.Mucosal vaccines: novel advances in technology and delivery.Topical immunization strategies.Aerosolized Non-viral Nucleic Acid Delivery in the Vaginal Tract of Pigs.Mucosal vaccines to prevent porcine reproductive and respiratory syndrome: a new perspective.Mucosal vaccine delivery: Current state and a pediatric perspective
P2860
Q24684754-D3031A8B-5270-4751-BC53-647856BDA6DDQ28087409-0E223793-78D2-4DB2-903C-9BEA9DBD7975Q30443793-AECD306B-A9A8-42FD-BD7B-748BC2199346Q33308325-3169AC98-1276-4F49-B894-2B9951CD156FQ33676056-6C0FC607-DC83-42A9-9228-99DDE442D299Q33716593-BC4A2FDA-8D4D-4522-A581-76A0B0F4F870Q33944566-63539664-E241-4EFD-9E47-273E0E306BF4Q34044915-87DF3061-F0D6-4D06-8D95-A4A7BAEA12F8Q34369729-D0128981-2946-4551-8D72-457BBEBF45CEQ34409172-8BF7EF3A-B075-4366-AF19-524B1198F89CQ34429327-6FA51506-2F9E-4455-8709-2B93755AAA4EQ34434903-E7851068-23AF-4CEF-A1A7-81D272D799AEQ34581660-BD89FABA-2C74-4570-A605-630E5932F602Q34598141-0E225BE8-95A3-487D-877D-C367F638F4D6Q34694812-F1D1207E-788E-428D-9E2C-BA9376940633Q34739969-65CD5386-3264-493F-A0F6-B63DE67B9077Q35061979-15842901-3CD7-49E9-AE0D-D3CF4FD13748Q35071155-2EB69A64-F280-4C68-ABE7-EF6C3F0C9500Q35550898-199D7FDF-F6B8-4144-96AC-BBA941A6F441Q35722157-FF9E8687-79A1-41A9-B0E2-0CDE77CB9067Q35757125-C12EAFCE-62D0-40D8-BCCF-402E4168AF5FQ35802015-F828BCFC-5361-4B87-8F31-6B3ABE78BE66Q35896020-BC3EA631-7EF8-430C-A8CF-6B0B4F85DFB7Q36099546-322E5668-DFA2-4405-AED3-E0F1A1457EADQ36209689-7C53F2EF-D717-433E-8294-816E700C6E35Q36218660-3D5795A1-B1A7-4089-9FBE-DE1BD44D91D2Q36735275-3DE33302-B19A-468D-B973-61E4139270B8Q36780136-26444BFA-3B83-46DD-BD89-C2EA8B34BDB4Q36804355-4195D6CD-E685-4727-9A44-472DEA920585Q36918159-04BE0D16-4E38-4DB8-BD2B-E69D95EEC877Q37133395-815BC2A7-949E-488B-A62A-E41C7218B35BQ37274559-CCA34935-686B-4F1C-93B2-487AD8D170FDQ37344236-881BDE6C-F857-4173-AD26-D6570EBA4AC0Q37461092-205A59FF-6B56-4D6A-959D-C5AE33B44FD1Q37478331-29CD3B5A-AA26-42ED-9A02-A526B1A185C9Q37559647-C5E1F1B5-F57F-43E4-B16D-60510AC2C24EQ37791415-21A51C49-6543-4E1E-8413-8635F96D2AC7Q37838639-1AAEA07A-74FA-4AD9-9417-D06EA5F321A3Q38020309-62A9002B-9C23-46AF-83F4-26A0604526C6Q38727453-140ADC57-640C-4763-84A4-AF13C8D7125A
P2860
Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Nasal and vaginal vaccinations ...... cervical secretions in humans.
@ast
Nasal and vaginal vaccinations ...... cervical secretions in humans.
@en
Nasal and vaginal vaccinations ...... cervical secretions in humans.
@nl
type
label
Nasal and vaginal vaccinations ...... cervical secretions in humans.
@ast
Nasal and vaginal vaccinations ...... cervical secretions in humans.
@en
Nasal and vaginal vaccinations ...... cervical secretions in humans.
@nl
prefLabel
Nasal and vaginal vaccinations ...... cervical secretions in humans.
@ast
Nasal and vaginal vaccinations ...... cervical secretions in humans.
@en
Nasal and vaginal vaccinations ...... cervical secretions in humans.
@nl
P2093
P2860
P1476
Nasal and vaginal vaccinations ...... cervical secretions in humans.
@en
P2093
P2860
P304
P356
10.1128/IAI.69.12.7481-7486.2001
P407
P50
P577
2001-12-01T00:00:00Z